Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Tonix Pharma, Kansas University Join Forces To Work On Next-Gen mRNA-Based COVID-19 Vaccine

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced an exclusive option agreement and research collaboration with Kansas State University (K-State) to develop zinc nanoparticle (ZNP) mRNA vaccines.

  • The ZNP technology replaces the lipid-nanoparticle (LNP) technology in current COVID-19 vaccines. 
  • Pfizer Inc (NYSE:PFE) - BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) COVID-19 shots are based on the LNP platform.
  • The new ZNP technology can confer increased stability to mRNA vaccines over a wide range of temperatures. 
  • Under the research agreement, K-State will advance the preclinical development of a new ZNP mRNA vaccine to protect against COVID-19 based on the spike protein from SARS-CoV-2.
  • Recently, the FDA signed off Tonix Pharma's Investigational New Drug (IND) application to initiate a human study for TNX-2100, a skin test to measure delayed-type hypersensitivity (DTH) to SARS-CoV-2.
  • Price Action: TNXP shares are up 3.96% at $0.41 during the premarket session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.